A Phase II Study of the Efficacy, Safety and Determinants of Response to 5-Azacitidine (Vidaza) in Patients With Chronic Myelomonocytic Leukemia (CMML).

Trial Profile

A Phase II Study of the Efficacy, Safety and Determinants of Response to 5-Azacitidine (Vidaza) in Patients With Chronic Myelomonocytic Leukemia (CMML).

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jun 2016

At a glance

  • Drugs Azacitidine (Primary) ; Azacitidine (Primary)
  • Indications Chronic myelomonocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Oct 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
    • 23 Jan 2014 According to ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
    • 24 Jul 2013 Planned End Date changed from 1 Dec 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top